Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Lilly’s Zepbound wins weight loss duel with Novo’s Wegovy
Eli Lilly’s Weight-Loss Drug Zepbound More Effective than Novo’s Wegovy, Study Shows
New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new efforts to market the drug as shortages ease. Recent months have brought new questions about whether the sky-high expectations for Zepbound’s sales—which have sent Lilly’s share price up more than 230% over the past three years—may be overly optimistic.
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
2h
Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
3d
on MSN
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...
1d
Eli Lilly & Co’s Promising Growth Driven by Mounjaro and Zepbound Performance
In a report released on December 6, Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Record 15-yr, $765M deal
Exits as RNC co-chair
Counselor to the president
Trump won't replace Powell
Accused in civil lawsuit
More drone sightings in NJ
Camerota to exit CNN
Today in history: 1965
‘Meet the Press’ interview
Andy Kim takes office early
Threat prompts evacuation
Delivers remarks on Syria
Fined for obscene gesture
Sailor laid to rest
CFP: 12-team bracket
Bomb threat targets Trahan
Producer Maslansky dies
Earth drier since 1990
Galaxy win 6th MLS Cup
MX flight diversion attempt
Tops box office again
Assad, family in Moscow?
Wins Ghana election
‘Dynasty' actor dies at 77
2024 likely hottest year
Murder suspect recaptured
$965 million verdict upheld
Studio pres dies in crash
Ruby slippers sell for $28M
US airstrikes hit ISIS camps
Israel shells Gaza hospital?
Feedback